Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming investor conferences. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s Web site at
. Celgene management will provide an overview of the Company.
Tuesday, March 5, 2013 Celgene will present at the Cowen and Company 33rd Annual Health Care Conference at 11:20 a.m. ET.
Thursday, March 14, 2013 Celgene will present at the Barclays Global Healthcare Conference at 8:30 a.m. ET.
Celgene will also
host a webcast of an investor event at the American Academy of Dermatology Annual Meeting on Sunday, March 3 at 6:00 p.m. ET. Members of Celgene’s management team and clinical investigators will discuss the ESTEEM-1 results in moderate-to-severe psoriasis. The meeting will be webcast live and will be available in the Investor Relations section of the Company’s web site at
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.